IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures. In addition, the company offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system that delivers laser to treat glaucoma; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe Illuminate and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products used in vitrectomy procedures. It serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. IRIDEX Corporation markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:IRIX
Previous Symbol
CUSIPN/A
Phone650-940-4700
Debt
Debt-to-Equity RatioN/A
Current Ratio3.98
Quick Ratio3.14
Price-To-Earnings
Trailing P/E Ratio-3.84
Forward P/E Ratio-3.91
P/E GrowthN/A
Sales & Book Value
Annual Sales$41.59 million
Price / Sales1.39
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.64 per share
Price / Book1.61
Profitability
EPS (Most Recent Fiscal Year)($1.11)
Net Income$-12,860,000.00
Net Margins-36.52%
Return on Equity-52.65%
Return on Assets-38.38%
Miscellaneous
Employees116
Outstanding Shares13,590,000
Market Cap$57.91 million
OptionableNot Optionable
IRIDEX (NASDAQ:IRIX) Frequently Asked Questions
What is IRIDEX's stock symbol?
IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."
How were IRIDEX's earnings last quarter?
IRIDEX Co. (NASDAQ:IRIX) released its earnings results on Thursday, November, 1st. The medical equipment provider reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.03. The medical equipment provider had revenue of $11.32 million for the quarter, compared to the consensus estimate of $9.64 million. IRIDEX had a negative net margin of 36.52% and a negative return on equity of 52.65%. View IRIDEX's Earnings History.
When is IRIDEX's next earnings date?
What price target have analysts set for IRIX?
2 equities research analysts have issued 1-year price targets for IRIDEX's shares. Their forecasts range from $9.00 to $10.00. On average, they anticipate IRIDEX's stock price to reach $9.50 in the next year. This suggests a possible upside of 123.0% from the stock's current price. View Analyst Price Targets for IRIDEX.
What is the consensus analysts' recommendation for IRIDEX?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IRIDEX.
Has IRIDEX been receiving favorable news coverage?
Press coverage about IRIX stock has been trending somewhat positive on Sunday, InfoTrie reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IRIDEX earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
Who are some of IRIDEX's key competitors?
Some companies that are related to IRIDEX include BioLife Solutions (BLFS), Semler Scientific (SMLR), Rockwell Medical (RMTI), Electrocore (ECOR), Fonar (FONR), Zynex (ZYXI), Second Sight Medical Products (EYES), Stereotaxis (STXS), Edap Tms (EDAP), Viveve Medical (VIVE), Soleno Therapeutics (SLNO), Precision Optics (PEYE), Digirad (DRAD), Nexeon Medsystems (NXNN) and ENDRA Life Sciences (NDRA).
Who are IRIDEX's key executives?
IRIDEX's management team includes the folowing people:
- Mr. William M. Moore, Chairman of Directors, Pres & CEO (Age 69)
- Mr. Atabak Mokari, CFO & VP of Corp. Devel. (Age 41)
- Dr. George R. Marcellino, VP of Clinical Affairs (Age 69)
- Ms. Leigh Salvo, Head of Investor Relations
- Mr. Timothy D. Buckley, VP of Global Marketing & Bus. Devel. (Age 43)
Who are IRIDEX's major shareholders?
IRIDEX's stock is owned by many different of institutional and retail investors. Top institutional investors include Acuta Capital Partners LLC (16.70%), Wasatch Advisors Inc. (11.40%), Vanguard Group Inc. (2.97%), Renaissance Technologies LLC (2.47%), Perkins Capital Management Inc. (1.95%) and Eidelman Virant Capital (1.31%). Company insiders that own IRIDEX stock include Associates & Paragon A Paragon, Romeo R Dizon and William M Moore. View Institutional Ownership Trends for IRIDEX.
Which institutional investors are selling IRIDEX stock?
Which institutional investors are buying IRIDEX stock?
IRIX stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Perkins Capital Management Inc., Eidelman Virant Capital, Quantum Capital Management, Renaissance Technologies LLC and Vanguard Group Inc.. Company insiders that have bought IRIDEX stock in the last two years include Associates & Paragon A Paragon and William M Moore. View Insider Buying and Selling for IRIDEX.
How do I buy shares of IRIDEX?
Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IRIDEX's stock price today?
One share of IRIX stock can currently be purchased for approximately $4.26.
How big of a company is IRIDEX?
IRIDEX has a market capitalization of $57.91 million and generates $41.59 million in revenue each year. The medical equipment provider earns $-12,860,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. IRIDEX employs 116 workers across the globe.
What is IRIDEX's official website?
How can I contact IRIDEX?
IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at 650-940-4700 or via email at [email protected]
MarketBeat Community Rating for IRIDEX (NASDAQ IRIX)
MarketBeat's community ratings are surveys of what our community members think about IRIDEX and other stocks. Vote "Outperform" if you believe IRIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
